CDH2 and hepatocellular carcinoma: Similar results had been obtained in hepatocellular carcinoma (HCC) and triple-negative breast cancer (TNBC) models in which FOXM1b dysregulation promoted the expression of mesenchymal markers, such as N-cadherin, Snail, and Zeb1, as well as the repression of the epithelial marker E-cadherin [82,83].